Steven Basta

Chief Executive Officer
Senior Executive with broad experience leading biopharma and medical technology companies.

Over the past 25 years, Steve has led multiple life science companies developing and commercializing biopharma and medical device technologies. Steve successfully led two Initial Public Offerings and multiple partnerships, private financings, mergers and licensing collaborations.

Steve led BioForm Medical through product development, initial commercial launch and scale up of a leading injectable aesthetics business, making it a worldwide leader in the dermal filler space, and ultimately a leader broadly in medical aesthetics. Steve led AlterG in establishing the AlterG anti-gravity treadmill as a core tool in physical therapy rehab for orthopedic and neurologic injury.

Steve holds a BA in biomedical engineering from Johns Hopkins and an MBA from Kellogg School of Management.

Gilly Regev, PhD

Chief Strategy and Innovation Officer, SaNOtize Cofounder
Experienced biotech executive with hands-on experience in launching pharmaceutical enterprises.

For the past 30 years, Dr. Regev has been a leader in biochemistry and microbiology R&D. She has extensive experience in drug development, intellectual property development, and clinical trials, as well as early-stage biotech fundraising and licensing deals.

Since co-founding SaNOtize in 2017, Dr. Regev has led the company from early research to an approved product and revenue generation in a very short time. She has also successfully capitalized the company through a significant Series B funding round and non-dilutive funding. Prior to SaNOtize, Dr. Regev spent twelve years in the field of nitric oxide, including as Chief Scientific Officer for Bovicor, an animal health company, and Director of R&D at Nitric Solutions, Inc. She earned her PhD in Biochemistry from the Hebrew University of Jerusalem.

In 2022, Dr. Regev was featured as one of the Top 25 Women Leaders in Biotechnology by the Healthcare Technology Report and in 2021 won a YWCA Women of Distinction Award as Entrepreneur and Innovator of the Year. Dr. Regev is also part of the Vancouver Chapter of the Weizmann Institute and a member of the Canadian Antimicrobial Innovation Coalition Steering Committee.

Chris Miller, PhD, BA, RT

Chris Miller, PhD, BA, RT

Chief Science Officer, SaNOtize Cofounder
A pioneer in nitric oxide technology and therapeutic research.

Dr. Miller has 30 years of experience in nitric oxide (NO) research, drug and device development, and commercialization. He has served as CEO/CSO in nitric oxide biotech startup fundraising and out licensing, and has expertise in clinical trial design and execution, intellectual property, regulatory affairs, and management.

Among his contributions, which include more than 40 peer-reviewed papers, Dr. Miller characterized one of the antimicrobial mechanisms of action of NO and identified its effective dose against multiple microbes including bacteria, fungi, and viruses. Dr. Miller also worked on the design of two of the first three FDA-approved NO gas delivery devices, and designed and completed the first human clinical trial demonstrating that inhaled NO was safe in healthy adults as a potential inhaled antimicrobial strategy.

Dr. Miller was an assistant professor in the Faculty of Medicine, Respiratory & Infectious Diseases Divisions at the University of British Columbia, Canada. He holds a PhD in Experimental Medicine and degrees in Health Management and Respiratory Therapy.

Keith Moore, PharmD, FCCP, BCPS

Chief Medical Officer
Clinician, inventor, author with experience in global drug and device research execution.

Dr. Moore has been a startup member of multiple pharmaceutical, R&D, and medical device companies. His 40-year career spans multiple areas of pharmaceutical research, including development, execution, and regulatory submissions of investigator-initiated and pharma-sponsored global Phase 1-4 clinical trials. Dr. Moore has experience in drug/device product development in small to large pharma organizations, with special focus on alternative modes of drug delivery, prodrug, pharmacokinetics, pharmacogenomics and OTC/505B2 development emphasis in respiratory, gastrointestinal, and infectious disease therapeutics.

Dr. Moore earned his PharmD from the University of Minnesota.

John Sharp, CPA

John Sharp, CPA

Chief Financial Officer
Senior financial executive with over 20 years of experience in corporate finance, accounting, and strategy within the life sciences industry.

Over his career, John has led successful fundraising for both private and public life sciences companies totaling nearly $400 million, and has led multiple mergers and acquisitions exceeding $140 million. John has extensive operational experience with pre-clinical, clinical, and commercial companies He has hands-on experience with both in-license and out-license of early and mid-stage product candidates. John holds a BS in Business Administration with an emphasis in Accounting and is a Certified Public Accountant in California.